Integrating Cobenfy Into Clinical Practice

Cobenfy is an important development in schizophrenia care. Clinically, Cobenfy has effectuated improvements in some symptom domains, with fewer adverse effects in short-term trials and compared with placebo. Conceptually, Cobenfy represents a renewed focus on improving outcomes in a field that has seen relatively limited therapeutic advancements. However, uncertainties regarding Cobenfy remain, leaving prescribers and patients with unanswered questions, particularly how, given the unknowns, Cobenfy should be introduced into clinical practice. In this Open Forum, the authors discuss the potential, promises, and challenges of integrating Cobenfy into clinical practice and propose a path forward, prioritizing choice and person-centered care.